Debates, in-depth articles, and surprising profiles from ASH Clinical News.

  • Cartwheels for CAR T-Cell Therapy? Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach to targeted immunotherapy to treat cancer, and the details can seem like the stuff of science fiction: A patient’s T cells are harvested, re-engineered to become targeted “cancer killers,” and infused back into the patient’s body to proliferate and eradicate cancer cells. In some cases, […]

  • Predatory Publishing: The Dark Side of the Open-Access Movement Thursday, December 29th, 2016 | January 2017, Volume 3, Issue 1

    In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker […]

  • Long-Term Impact of the ASH Scholar Award Program Tuesday, November 22nd, 2016 | December 2016, Volume 2, Issue 12

    The American Society of Hematology’s (ASH) longest-running award program, the ASH Scholar Award, celebrates more than 30 years of financially supporting fellows and junior faculty as they transition from training programs to careers as independent investigators. Since 1985, ASH has contributed over $41 million in Scholar Award grants and has provided 377 Scholar Awards. This […]

  • A Way With Words: David Steensma, MD Tuesday, November 22nd, 2016 | December 2016, Volume 2, Issue 12 | David Steensma, MD

    In this edition, David Steensma, MD, shares his lifelong love of word games and how he went from fighting over the newspaper puzzle page to crafting crosswords for ASH annual meeting attendees. When did your interest in crossword puzzles start? Did you enjoy puzzles growing up? My mother has long been an avid “cruciverbalist” – […]

  • To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable? Tuesday, November 22nd, 2016 | December 2016, Volume 2, Issue 12 | Larisa H. Cavallari, PharmD

    Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug levels a challenge. Researchers are now investigating whether adding genomic information to dosing algorithms could better identify the optimal starting dose for patients new to warfarin, minimize variability in drug response, […]

1 of 15
back to top